Machine Learning Models for Predicting Bleeding Risk in Anticoagulated Patients with Atrial Fibrillation and Venous

Winnie Z Y Teo1,2,3,4, Maggie Wing Yin Wong1,2,3,4, Fang Jin Lim2,3

  • 1Department of Haematology-Oncology, National University Cancer Institute, Singapore 119074, Singapore.

Background: Accurate prediction of bleeding events in patients receiving oral anticoagulants remains a key challenge in the management of atrial fibrillation (AF) and venous thromboembolism (VTE). Machine learning (ML) algorithms have emerged as powerful tools that capture complex, nonlinear interactions among risk factors, potentially offering superior accuracy. Objectives: To synthesize evidence comparing ML-based bleeding risk models with conventional clinical scores in anticoagulated AF and VTE populations. Methods: We conducted a systematic review with narrative synthesis of studies published between 2015 and 2025 applying ML algorithms to predict bleeding events in anticoagulated AF or VTE patients. Results: Thirteen studies were identified (seven AF and six VTE), including 464,523 participants in total. ML algorithms such as random forest (RF), extreme gradient boosting (XGBoost), and neural networks consistently outperformed traditional tools. In AF, AUCs ranged from 0.64 to 0.76 compared to 0.52-0.61 for HAS-BLED. In VTE, ML models achieved 0.59-0.91 versus 0.61-0.65 for RIETE or VTE-BLEED. Deep learning ensembles reached the highest AUCs (>0.8). Conclusions: ML-based bleeding risk models demonstrated statistically superior discrimination compared to established scores in both AF and VTE contexts, but effect sizes were modest (ΔAUC 0.05-0.15) and clinical utility remains uncertain. Broader validation, calibration assessment, and demonstration of impact on clinical outcomes are necessary before routine adoption.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
465
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
379
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K